- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02902926
Comparison of Microbiota and Quality of Life for a Low FODMAPs and Standard Dietary in Irritable Bowel Syndrome Patients
Comparison of Microbiota and Quality of Life for a Low FODMAPs Versus Standard Dietary Advice in Patients With Irritable Bowel Syndrome
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
IBS is a global disease, patients often because of long-term symptoms of recurrent, not timely diagnosis and treatment effect is not ideal and frequent treatment, seriously affect the quality of life, and cause the corresponding economic and social burden.At present,a number of studies suggest that fermentable oligosaccharides, disaccharides and monosaccharides and polyols (FODMAPs) can induce IBS symptoms.Data from large randomized controlled trials are limited, leaving clinicians with the challenge of providing patients with reliable guidance based on minimal evidence.
This study will compare the effect of low FODMAPs diet and usual diet instruction on Intestinal flora, intestinal short chain fatty acids and quality of life by two groups.The results will answer the effect and long-term safety of Low FODMAPs diet.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Jiangsu
-
Yangzhou, Jiangsu, Kina, 225001
- Rekruttering
- YangzhouUniversity
-
Ta kontakt med:
- Tianqi Zhou, Dr.
- Telefonnummer: +8618852727248
- E-post: 651299080@qq.com
-
Ta kontakt med:
- Yamei Gu, Dr.
- Telefonnummer: +8615252573426
- E-post: 286508374@qq.com
-
Hovedetterforsker:
- Jinsong Wang, Ph.D.,M.D.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnostic criteria for Rome Ⅲ
- IBS patients with diarrhea type
- By endoscopy, X-ray, B ultrasound and laboratory examination to exclude organic disease
- Patients be able to communicate well with the researchers and be willing to participate in the study
Exclusion Criteria:
- Stomach, small intestine, colon surgery history
- irritable bowel disease (IBD) active period, celiac disease
- Alcoholics or drug abuse
- Pregnant or lactating women
- Recent drug users who use defecation
- Have a special diet
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Low FODMAPs Diet
|
Instruct to design and eat Low Fermentable,Oligo-,Di-,Mono-saccharides And Polyols(FODMAPs) Diet
Answer the doubt and help the patient get the diet knowlege about the IBS.
|
Placebo komparator: Diet Instruction
1.Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.
|
Answer the doubt and help the patient get the diet knowlege about the IBS.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Microbiota / Short chain fatty acids
Tidsramme: Change from baseline Microbiota / Short chain fatty acids at 4 weeks
|
The fecal samples of IBS patients were analyzed.
|
Change from baseline Microbiota / Short chain fatty acids at 4 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Irritable bowel syndrome severity scoring system scale
Tidsramme: Baseline,1,and 3 month post randomization
|
Irritable bowel syndrome severity scoring system scale is an integral system for monitoring the severity of IBS in patients with disease severity.The scale is mainly from the degree of abdominal pain, abdominal pain frequency, abdominal distension, defecation satisfaction and the impact of life, according to the 10cm visual scoring method
|
Baseline,1,and 3 month post randomization
|
The Short Form 36 (SF-36) scale
Tidsramme: Baseline,1,and 3 month post randomization
|
SF-36 is a general scale, at present, the most commonly used evaluation of IBS.
It includes 36 items, a total of 8 dimensions
|
Baseline,1,and 3 month post randomization
|
Irritable bowel syndrome quality of life (IBS-QOL) scale
Tidsramme: Baseline,1,and 3 month post randomization
|
Irritable bowel syndrome quality of life (IBS-QOL) scale is a more extensive application of the specific scale of IBS.
|
Baseline,1,and 3 month post randomization
|
Satisfaction questionnaire
Tidsramme: 1,and 3 month post randomization
|
To understand the patient's satisfaction with symptom control and diet guidance.
The questionnaire included 3 items
|
1,and 3 month post randomization
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Hongcan Shi, Ph.D.,M.D., Medical College
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014 Nov;40(9):1023-34. doi: 10.1111/apt.12938. Epub 2014 Sep 9.
- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4. doi: 10.1016/j.cgh.2012.02.029. Epub 2012 Mar 15.
- Eswaran S, Tack J, Chey WD. Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am. 2011 Mar;40(1):141-62. doi: 10.1016/j.gtc.2010.12.012.
- Bohn L, Storsrud S, Tornblom H, Bengtsson U, Simren M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol. 2013 May;108(5):634-41. doi: 10.1038/ajg.2013.105.
- Iacovou M, Tan V, Muir JG, Gibson PR. The Low FODMAP Diet and Its Application in East and Southeast Asia. J Neurogastroenterol Motil. 2015 Oct 1;21(4):459-70. doi: 10.5056/jnm15111.
- De Giorgio R, Volta U, Gibson PR. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction? Gut. 2016 Jan;65(1):169-78. doi: 10.1136/gutjnl-2015-309757. Epub 2015 Jun 15.
- Gibson PR, Varney J, Malakar S, Muir JG. Food components and irritable bowel syndrome. Gastroenterology. 2015 May;148(6):1158-74.e4. doi: 10.1053/j.gastro.2015.02.005. Epub 2015 Feb 11.
- Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol. 2014 Jul 21;20(27):8859-66. doi: 10.3748/wjg.v20.i27.8859.
- Jain I, Kumar V, Satyanarayana T. Xylooligosaccharides: an economical prebiotic from agroresidues and their health benefits. Indian J Exp Biol. 2015 Mar;53(3):131-42.
- Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014 Jan;146(1):67-75.e5. doi: 10.1053/j.gastro.2013.09.046. Epub 2013 Sep 25.
- Bohn L, Storsrud S, Liljebo T, Collin L, Lindfors P, Tornblom H, Simren M. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015 Nov;149(6):1399-1407.e2. doi: 10.1053/j.gastro.2015.07.054. Epub 2015 Aug 5.
- Whigham L, Joyce T, Harper G, Irving PM, Staudacher HM, Whelan K, Lomer MC. Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome. J Hum Nutr Diet. 2015 Dec;28(6):687-96. doi: 10.1111/jhn.12318. Epub 2015 Apr 14.
- Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr. 2016 Apr;55(3):897-906. doi: 10.1007/s00394-015-0922-1. Epub 2015 May 17.
- Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, Versalovic J, Shulman RJ. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther. 2015 Aug;42(4):418-27. doi: 10.1111/apt.13286. Epub 2015 Jun 24.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 20160805
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Matvaner
-
Biomerics, LLCUkjent
-
Washington State UniversityNational Center for Complementary and Integrative Health (NCCIH)FullførtInteraksjon Drug FoodForente stater
-
Washington State UniversityNational Center for Complementary and Integrative Health (NCCIH); Office...Aktiv, ikke rekrutterendeInteraksjon Drug FoodForente stater
-
Washington State UniversityNational Center for Complementary and Integrative Health (NCCIH)FullførtInteraksjon Drug FoodForente stater
-
HealthPartners InstituteFullført
-
Hebrew University of JerusalemPåmelding etter invitasjonMatrespons | Matstopp | Food Response-hemmingIsrael
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do SulUkjentAldring | Interaksjon Drug Food | Primær hypotyreoseBrasil
Kliniske studier på Low FODMAPs Diet
-
Cairo UniversityRekrutteringOvervekt | Irritabel tarm-syndrom | Abdominal fedmeEgypt
-
Azienda di Servizi alla Persona di PaviaFullførtIrritabel tarm-syndrom | Boswellia SerrataItalia
-
Oh Yoen KimDong-A UniversityFullført
-
Terry L. WahlsNational Multiple Sclerosis SocietyAktiv, ikke rekrutterendeMultippel sklerose | Multippel sklerose, tilbakefallende-remitterendeForente stater
-
University Hospital Schleswig-HolsteinTilbaketrukket
-
University of MichiganFullført
-
Beth Israel Deaconess Medical CenterUniversity of MichiganAktiv, ikke rekrutterende
-
Tel-Aviv Sourasky Medical CenterUkjentIrritabel tarm-syndromIsrael
-
Universitair Ziekenhuis BrusselRekrutteringIrritabel tarm-syndromBelgia
-
University of ZurichUkjentFunksjonelle gastrointestinale lidelserSveits